Iovance Biotherapeutics Inc. (IOVA), a commercial-stage biopharmaceutical company, on Monday announced FDA clearance of the investigational new drug (IND) submission for IOV-5001, a tumor-infiltrating lymphocyte (TIL) therapy.
IOV-5001 was engineered to express the interleukin IL-12 within the targeted tumor and tethers the IL-12 to the cell surface to prevent release into the bloodstream, thus delivering significantly higher doses to the cancer cell. In preclinical studies, IOV-5001 showed consistent anti-tumor activity and a more durable T cell profile compared to existing TIL therapies.
The company plans to initiate enrollment in a Phase 1/2 trial in the second half of 2026. The trial is expected to enroll patients with advanced colorectal, triple-negative, and estrogen receptor-low breast cancers, and other solid tumors.
IOVA closed Monday at $3.96, down 3.41%. In the pre-market, shares are trading at $3.97, down 0.03%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.